# The paired immunoglobulin-like type 2 receptor alpha (PILRA) gene polymorphism rs1859788 reduces risk of Alzheimer’s Disease in men homozygous for the ApoE ε4 allele

**Authors:** Steven Lehrer, Peter Rheinstein

PMC · DOI: 10.21203/rs.3.rs-4798019/v1 · Research Square · 2024-07-29

## TL;DR

A genetic variant in the PILRA gene reduces Alzheimer's risk in men with a specific APOE gene form, but not in women.

## Contribution

The study identifies a gender-specific protective effect of the PILRA rs1859788 SNP in men homozygous for APOE ε4.

## Key findings

- The PILRA rs1859788 AA genotype significantly reduces Alzheimer's risk in men with APOE ε4/ε4.
- The protective effect of PILRA rs1859788 is not observed in women with APOE ε4/ε4.
- PILRA rs1859788 is associated with megaloblastic anemia, potentially linking AD and anemia.

## Abstract

The APOE gene has long been associated with Alzheimer Disease (AD) risk. Emerging research indicates that other genetic loci, including the paired immunoglobulin-like type 2 receptor alpha (PILRA) gene, may play a crucial role. In the current study we used UK Biobank data to assess the relationship between PILRA and AD.

We examined the PILRA polymorphism rs1859788, a single nucleotide missense variant, G > A, minor allele frequency 0.3. Single nucleotide polymorphism (SNP) data for rs429358 and rs7412 determined APOE isoform. We used PheWeb to perform a phenome wide association study (phewas) of rs1859788 and identify other conditions that might be related to both AD and rs1859788.

In male subjects homozygous for ApoE isoform ε4/ε4, of the men without AD, 9.7% had AA genotype; of the men with AD, 1.8% had AA genotype. This difference was significant (p = 0.006, two tail Fisher exact test). In female subjects homozygous for ApoE isoform ε4/ε4, of the women without AD, 10.4% had AA genotype; of the women with AD 7.9% had AA genotype. This difference was not significant (p = 0.481). In subjects not homozygous for ApoE isoform ε4/ε4, the effect of PILRA genotype was not significant. A phewas of rs1859788 found an association with megaloblastic anemia.

We have confirmed the previously noted PILRA snp rs1859788 risk reduction of AD, as well as a PILRA link to the ApoE ε4 isoform that has been previously described. We are uncertain why the significant association is only with men who are homozygous for the ε4/ε4 isoform. A phewas indicated that PILRA SNP rs1859788 is associated with megaloblastic anemia, which may explain an observed association between AD and anemia. The identification of PILRA as a potential risk gene for Alzheimer’s disease underscores the complexity of the genetic landscape contributing to AD. Alongside APOE, PILRA may play a significant role in modulating key pathological processes such as neuroinflammation and amyloid-beta accumulation.

## Linked entities

- **Genes:** PILRA (paired immunoglobin like type 2 receptor alpha) [NCBI Gene 29992], APOE (apolipoprotein E) [NCBI Gene 348]
- **Proteins:** APOE (apolipoprotein E), UBE4A (ubiquitination factor E4A)
- **Diseases:** Alzheimer’s Disease (MONDO:0004975), megaloblastic anemia (MONDO:0001700)

## Full-text entities

- **Genes:** PILRA (paired immunoglobin like type 2 receptor alpha) [NCBI Gene 29992] {aka FDF03}, APP (amyloid beta precursor protein) [NCBI Gene 351] {aka AAA, ABETA, ABPP, AD1, APPI, CTFgamma}, APOE (apolipoprotein E) [NCBI Gene 348] {aka AD2, APO-E, ApoE4, LDLCQ5, LPG}
- **Diseases:** anemia (MESH:D000740), megaloblastic anemia (MESH:D000749), AD (MESH:D000544), neuroinflammation (MESH:D000090862)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** G > A, rs1859788, rs7412, rs429358

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11326400/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC11326400/full.md

## References

11 references — full list in the complete paper: https://tomesphere.com/paper/PMC11326400/full.md

---
Source: https://tomesphere.com/paper/PMC11326400